Maintenance of Response With up to 4 Years of Continuous Guselkumab Treatment: Results From the VOYAGE 1 Phase 3 Trial. J of Skin [Internet]. 2019 Nov. 9 [cited 2025 Apr. 19];3:S17. Available from: https://skin.dermsquared.com/skin/article/view/744